Efficacy and safety of denosumab treatment for Korean patients with Stage 3b–4 chronic kidney disease and osteoporosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: We evaluated the efficacy and safety of denosumab treatment in severe chronic kidney disease (CKD) patients with osteoporosis. We also investigated whether the treatment affects the coronary artery calcifications. Methods: Twenty-seven postmenopausal women with Stage 3b–4 CKD and osteoporosis were enrolled. Twenty patients received denosumab plus calcium carbonate and vitamin D, and seven controls received calcium carbonate and vitamin D for 1 year. Dual-energy X-ray absorptiometry and coronary artery calcium (CAC) scoring computed tomography were performed before and after treatment. Hypocalcemic symptoms and serum calcium levels were evaluated. Results: After 1 year of treatment, the percent changes of femur neck (3.6 ± 3.2% vs. -0.7 ± 4.4%, p = 0.033) and total hip (3.4 ± 3.8% vs. -1.9 ± 2.1%, p = 0.001) bone mineral density (BMD) were significantly increased in the denosumab treated group compared to the control group. However, the percent change of lumbar spine BMD did not differ between two groups (5.6 ± 5.9% vs. 2.7 ± 3.9%, p = 0.273). The percent change of bone alkaline phosphatase was significantly different in the denosumab-treated group and control group (-31.1 ± 30.0% vs. 0.5 ± 32.0%, p = 0.027). CAC scores did not differ between groups. No hypocalcemic events occurred in both groups. Conclusions: If carefully monitored and supplemented with calcium and vitamin D, denosumab treatment for 1 year provides significant benefits in patients with Stage 3b–4 CKD and osteoporosis. However, denosumab treatment did not affect coronary artery calcifications in these patients.
Abstract
Background/Aims: We evaluated the efficacy and safety of denosumab treatment in severe chronic kidney disease (CKD) patients with osteoporosis. We also investigated whether the treatment affects the coronary artery calcifications. Methods: Twenty-seven postmenopausal women with Stage 3b–4 CKD and osteoporosis were enrolled. Twenty patients received denosumab plus calcium carbonate and vitamin D, and seven controls received calcium carbonate and vitamin D for 1 year. Dual-energy X-ray absorptiometry and coronary artery calcium (CAC) scoring computed tomography were performed before and after treatment. Hypocalcemic symptoms and serum calcium levels were evaluated. Results: After 1 year of treatment, the percent changes of femur neck (3.6 ± 3.2% vs. -0.7 ± 4.4%, p = 0.033) and total hip (3.4 ± 3.8% vs. -1.9 ± 2.1%, p = 0.001) bone mineral density (BMD) were significantly increased in the denosumab treated group compared to the control group. However, the percent change of lumbar spine BMD did not differ between two groups (5.6 ± 5.9% vs. 2.7 ± 3.9%, p = 0.273). The percent change of bone alkaline phosphatase was significantly different in the denosumab-treated group and control group (-31.1 ± 30.0% vs. 0.5 ± 32.0%, p = 0.027). CAC scores did not differ between groups. No hypocalcemic events occurred in both groups. Conclusions: If carefully monitored and supplemented with calcium and vitamin D, denosumab treatment for 1 year provides significant benefits in patients with Stage 3b–4 CKD and osteoporosis. However, denosumab treatment did not affect coronary artery calcifications in these patients.
참고문헌 (30)
- Connelly K, "Fracture risk and treatment in chronic kidney disease", Curr Opin Nephrol Hypertens, 27, pp.221~225 (2018)
- Damasiewicz MJ, "Rethinking bone disease in kidney disease", JBMR Plus, 2, pp.309~322 (2018)
- Kidney Disease : Improving Global Outcomes(KDIGO)CKDMBD Update Work Group, "KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD)", Kidney Int Suppl(2011), 7, pp.1~59 (2017)
- Cummings SR, "Denosumab for prevention of fractures in postmenopausal women with osteoporosis", N Engl J Med, 361, pp.756~765 (2009)
- Block GA, "A single-dose study of denosumab in patients with various degrees of renal impairment", J Bone Miner Res, 27, pp.1471~1479 (2012)
- Broadwell A, "Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease", J Clin Endocrinol Metab, 106, pp.397~409 (2021)
- McCormick BB, "Severe hypocalcemia following denosumab injection in a hemodialysis patient", Am J Kidney Dis, 60, pp.626~628 (2012)
- Ungprasert P, "Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency", Am J Emerg Med, 31, pp.756~ (2013)
- Krueger D, "ISCD in 2015 : state of the society", J Clin Densitom, 18, pp.445~446 (2015)
- Carr JJ, "Calcified coronary artery plaque measurement with cardiac CT in population-based studies : standardized protocol of Multi-Ethnic Study of Atherosclerosis(MESA)and Coronary Artery Risk Development in Young Adults(CARDIA)study", Radiology, 234, pp.35~43 (2005)
- Agatston AS, "Quantification of coronary artery calcium using ultrafast computed tomography", J Am Coll Cardiol, 15, pp.827~832 (1990)
- Pletcher MJ, "Using the coronary artery calcium score to predict coronary heart disease events : a systematic review and meta-analysis", Arch Intern Med, 164, pp.1285~1292 (2004)
- Kunizawa K, "Denosumab for dialysis patients with osteoporosis : a cohort study", Sci Rep, 10, pp.2496~ (2020)
- Henriksen K, "A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D", Bone, 91, pp.122~129 (2016)
- Bezerra de Carvalho KS, "Chronic kidney disease is associated with low BMD at the hip but not at the spine", Osteoporos Int, 30, pp.1015~1023 (2019)
- Inker LA, "New creatinine- and cystatin C-based equations to estimate GFR without race", N Engl J Med, 385, pp.1737~1749 (2021)
- Dave V, "Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5", Am J Nephrol, 41, pp.129~137 (2015)
- Huynh AL, "Denosumab-associated hypocalcaemia : incidence, severity and patient characteristics in a tertiary hospital setting", Pharmacoepidemiol Drug Saf, 25, pp.1274~1278 (2016)
- Hwang E, "Management of chronic kidney disease-mineral and bone disorder : Korean working group recommendations", Kidney Res Clin Pract, 34, pp.4~12 (2015)
- Chiang C, "The use of bone turnover markers in chronic kidney disease-mineral and bone disorders", Nephrology (Carlton), 22(Suppl 2), pp.11~13 (2017)
- Regidor DL, "Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients", J Am Soc Nephrol, 19, pp.2193~2203 (2008)
- Yamada S, "Utility of serum tartrate-resistant acid phosphatase(TRACP5b)as a bone resorption marker in patients with chronic kidney disease : independence from renal dysfunction", Clin Endocrinol(Oxf), 69, pp.189~196 (2008)
- Wu M, "Vascular calcification : an update on mechanisms and challenges in treatment", Calcif Tissue Int, 93, pp.365~373 (2013)
- Tintut Y, "Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification", J Investig Med, 54, pp.395~401 (2006)
- Suzuki S, "Denosumab recovers aortic arch calcification during long-term hemodialysis", Kidney Int Rep, 6, pp.605~612 (2020)
- Samelson EJ, "RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk", J Bone Miner Res, 29, pp.450~457 (2014)
- Menon V, "Relationship between homocysteine and mortality in chronic kidney disease", Circulation, 113, pp.1572~1577 (2006)
- McLean RR, "Homocysteine as a predictive factor for hip fracture in older persons", N Engl J Med, 350, pp.2042~2049 (2004)
- Gjesdal CG, "Plasma total homocysteine level and bone mineral density : the Hordaland Homocysteine Study", Arch Intern Med, 166, pp.88~94 (2006)
- van Meurs JB, "Homocysteine levels and the risk of osteoporotic fracture", N Engl J Med, 350, pp.2033~2041 (2004)